Eli Lilly just dropped $1 billion—plus a $300 million bonus if trials go well—on gene therapy firm Verve, aiming to spice up ...

Global shares are mostly higher and oil prices have slipped as investors await a decision on interest rates by the Federal ...

Eli Lilly’s LLY recent announcement to acquire Verve Therapeutics, Inc VERV, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, has put the spotlight on ...

Nucor shares are rising Wednesday after the steelmaker outlined better second-quarter profit projections than analysts had ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

The deal, announced June 17, includes a cash offer of $10.50 per share for all outstanding Verve stock. Lilly may also pay as ...

Streaming Finally Outpaces Traditional TV. The Leading Platform Might Surprise You. YouTube represented 12.5% of all television viewing in May-the highest share of TV for any streamer to date. The new ...

Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...

The plane maker is betting that demand for aircraft will continue to fuel growth in coming years. The systems will be jointly developed and produced by the two companies, with suppliers and industrial ...